

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3084593/publications.pdf>

Version: 2024-02-01

155
papers

7,294
citations

71102

41
h-index

56724

83
g-index

159
all docs

159
docs citations

159
times ranked

4826
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunological mechanisms of allergen-specific immunotherapy. <i>Nature Reviews Immunology</i> , 2006, 6, 761-771.	22.7	686
2	The role of T lymphocytes in the pathogenesis of asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 450-463.	2.9	521
3	Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. <i>Lancet, The</i> , 2002, 360, 47-53.	13.7	353
4	Immunoglobulin Eâ€“independent Major Histocompatibility Complexâ€“restricted T Cell Peptide Epitopeâ€“induced Late Asthmatic Reactions. <i>Journal of Experimental Medicine</i> , 1999, 189, 1885-1894.	8.5	328
5	Peptide-based therapeutic vaccines for allergic and autoimmune diseases. <i>Nature Medicine</i> , 2005, 11, S69-S76.	30.7	290
6	Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. <i>Journal of Immunology</i> , 1997, 158, 3539-44.	0.8	273
7	Functional rather than immunoreactive levels of IgG₄ correlate closely with clinical response to grass pollen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 217-226.	5.7	254
8	Tregs and allergic disease. <i>Journal of Clinical Investigation</i> , 2004, 114, 1389-1397.	8.2	235
9	Peptide immunotherapy in allergic asthma generates IL-10â€“dependent immunological tolerance associated with linked epitope suppression. <i>Journal of Experimental Medicine</i> , 2009, 206, 1535-1547.	8.5	192
10	Fel d 1â€“derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 103-109.e7.	2.9	184
11	Regulatory T Cells in Allergy and Asthma. <i>Chest</i> , 2007, 132, 1007-1014.	0.8	178
12	Allergen-Derived T Cell Peptide-Induced Late Asthmatic Reactions Precede the Induction of Antigen-Specific Hyporesponsiveness in Atopic Allergic Asthmatic Subjects. <i>Journal of Immunology</i> , 2001, 167, 1734-1739.	0.8	171
13	Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 89-97.e14.	2.9	159
14	T Cell Epitope Immunotherapy Induces a CD4+ T Cell Population with Regulatory Activity. <i>PLoS Medicine</i> , 2005, 2, e78.	8.4	145
15	The IgE-facilitated allergen binding (FAB) assay: Validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. <i>Journal of Immunological Methods</i> , 2006, 317, 71-79.	1.4	138
16	Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. <i>Clinical and Experimental Allergy</i> , 2006, 36, 465-474.	2.9	131
17	Tregs and allergic disease. <i>Journal of Clinical Investigation</i> , 2004, 114, 1389-1397.	8.2	131
18	IL-5 secretion by allergen-stimulated CD4+ T cells in primary culture: Relationship to expression of allergic disease. <i>Journal of Allergy and Clinical Immunology</i> , 1997, 99, 563-569.	2.9	118

#	ARTICLE	IF	CITATIONS
19	The effect of Fel d 1â€derived Tâ€cell peptides on upper and lower airway outcome measurements in catâ€allergic subjects. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2005, 60, 1269-1274.	5.7	117
20	Fel d 1â€derived synthetic peptide immunoâ€regulatory epitopes show a longâ€term treatment effect in cat allergic subjects. <i>Clinical and Experimental Allergy</i> , 2015, 45, 974-981.	2.9	102
21	Fel d 1â€derived T cell peptide therapy induces recruitment of CD4⁺CD25⁺; CD4⁺ interferonâ€³⁺ T helper type 1 cells to sites of allergenâ€induced lateâ€phase skin reactions in catâ€allergic subjects. <i>Clinical and Experimental Allergy</i> , 2005, 35, 52-58.	2.9	101
22	Update on the current status of peptide immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 906-909.	2.9	93
23	Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future â€“ an <scp>EAACI</scp> Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1035-1042.	5.7	85
24	Immunotherapy with peptides. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 784-791.	5.7	82
25	Hyper IgM syndrome associated with defective CD40-mediated B cell activation.. <i>Journal of Clinical Investigation</i> , 1994, 94, 1404-1409.	8.2	81
26	Perspectives in allergen immunotherapy: 2017 and beyond. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 5-23.	5.7	76
27	Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double-blind placebo-controlled study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2004, 59, 1097-1101.	5.7	72
28	Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics. <i>Journal of Immunology</i> , 1998, 161, 6375-82.	0.8	72
29	Allergen immunotherapy on the way to product-based evaluationâ€”a WAO statement. <i>World Allergy Organization Journal</i> , 2015, 8, 29.	3.5	70
30	Late Asthmatic Reactions Induced by Inhalation of Allergen-derived T Cell Peptides. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 20-26.	5.6	69
31	Novel approaches and perspectives in allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1022-1034.	5.7	68
32	Peptide immunotherapy for allergic diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 325-331.	5.7	65
33	Peptide-Mediated Immune Responses in Specific Immunotherapy. <i>International Archives of Allergy and Immunology</i> , 2000, 122, 229-237.	2.1	61
34	Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or TH2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 394-401.	2.9	59
35	Immunoregulation by targeting T cells in the treatment of allergy and asthma. <i>Current Opinion in Immunology</i> , 2006, 18, 745-750.	5.5	58
36	The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. <i>European Respiratory Journal</i> , 2001, 18, 45-52.	6.7	57

#	ARTICLE	IF	CITATIONS
37	New Directions in Immunotherapy. <i>Current Allergy and Asthma Reports</i> , 2013, 13, 178-195.	5.3	54
38	Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 486-496.	2.9	52
39	Myasthenia gravis thymus: Clinical, histological and culture correlations. <i>Journal of Autoimmunity</i> , 1988, 1, 445-467.	6.5	46
40	Blood eosinophils from atopic donors express messenger RNA for the $\hat{1}\pm$, $\hat{1}^2$, and $\hat{1}^3$ subunits of the high-affinity IgE receptor (Fc $\hat{1}\mu$ RI) and intracellular, but not cell surface, $\hat{1}\pm$ subunit protein. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, 309-317.	2.9	44
41	Airway expression of calcitonin gene-related peptide in T-cell peptide-induced late asthmatic reactions in atopics. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 495-503.	5.7	41
42	T Cell Epitope-Based Allergy Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2011, 352, 107-119.	1.1	41
43	One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 454-468.	5.7	39
44	Developmental T cell receptor gene rearrangements: Relatedness of the $\hat{1}\pm/\hat{1}^2$ and $\hat{1}^3/\hat{1}^1$ T cell precursor. <i>European Journal of Immunology</i> , 1991, 21, 1939-1950.	2.9	38
45	A single strand conformation polymorphism study of CD40 ligand. Efficient mutation analysis and carrier detection for X-linked hyper IgM syndrome.. <i>Journal of Clinical Investigation</i> , 1996, 97, 196-201.	8.2	36
46	Proliferation and release of IL-5 and IFN- $\hat{1}^3$ by peripheral blood mononuclear cells from cat-allergic asthmatics and rhinitics, non-cat-allergic asthmatics, and normal controls to peptides derived from Fel d 1 chain 1. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 349-356.	2.9	35
47	An Update on Lymphocyte Subtypes in Asthma and Airway Disease. <i>Chest</i> , 2017, 151, 1122-1130.	0.8	35
48	Mechanisms of Peptide Immunotherapy in Allergic Airways Disease. <i>Annals of the American Thoracic Society</i> , 2014, 11, S292-S296.	3.2	33
49	Peptide-based vaccination: where do we stand?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2005, 5, 537-543.	2.3	32
50	Peptide-based immunotherapy: a novel strategy for allergic disease. <i>Expert Review of Vaccines</i> , 2005, 4, 881-889.	4.4	31
51	Comparison of house dust mite sensitization profiles in allergic adults from Canada, Europe, South Africa and USA. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2177-2188.	5.7	31
52	Peptide therapy for allergic diseases: Basic mechanisms and new clinical approaches. , 2005, 108, 353-361.		28
53	Natural regulatory T cells in isolated early responders compared with dual responders with allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 696-703.	2.9	28
54	Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy?. <i>British Journal of Cancer</i> , 1989, 59, 910-914.	6.4	26

#	ARTICLE	IF	CITATIONS
55	Functional evidence for a monoclonal antibody that binds to the human IL-4 receptor. <i>Immunology</i> , 1988, 65, 617-22.	4.4	26
56	Modulation of CRTh2 expression on allergen-specific T cells following peptide immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2157-2166.	5.7	25
57	T regulatory cell phenotypes in peripheral blood and bronchoalveolar lavage from non-asthmatic and asthmatic subjects. <i>Clinical and Experimental Allergy</i> , 2015, 45, 1654-1662.	2.9	24
58	Nasal allergen challenge and environmental exposure chamber challenge: A randomized trial comparing clinical and biological responses to cat allergen. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1585-1597.	2.9	23
59	Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3589-3612.	5.7	23
60	Inhibition of alloreactivity by mAb MR6: differential effects on IL-2- and IL-4-producing human T cells. <i>International Immunology</i> , 1994, 6, 1575-1584.	4.0	22
61	Airway hyperresponsiveness and bronchial mucosal inflammation in T cell peptide-induced asthmatic reactions in atopic subjects. <i>Thorax</i> , 2007, 62, 750-757.	5.6	22
62	Diversity of T-cell receptor alpha gene transcripts in the newborn and adult periphery. <i>Immunogenetics</i> , 1992, 36, 95-103.	2.4	19
63	Specific immunotherapy. <i>British Medical Bulletin</i> , 2000, 56, 1019-1036.	6.9	19
64	Inhibition of human T-cell responses by allergen peptides. <i>Immunology</i> , 2001, 104, 377-382.	4.4	19
65	Indirect Recognition of T-Cell Epitopes Derived from the β 3 and Transmembrane Domain of HLA-A2. <i>American Journal of Transplantation</i> , 2007, 7, 1148-1157.	4.7	19
66	Amelioration of ovalbumin-induced allergic airway disease following Der p 1 peptide immunotherapy is not associated with induction of IL-35. <i>Mucosal Immunology</i> , 2014, 7, 379-390.	6.0	19
67	Immunotherapy with Allergen Peptides. <i>Allergy, Asthma and Clinical Immunology</i> , 2007, 3, 53.	2.0	18
68	Safety and Tolerability of Escalating Doses of House Dust Mite- Peptide Antigen Desensitization (HDM-PAD). <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB37.	2.9	18
69	A novel T-lymphocyte molecule that may function in the induction of self-tolerance and MHC-restriction within the human thymic microenvironment. <i>Immunology</i> , 1988, 64, 101-5.	4.4	18
70	T cell-mediated induction of thymic stromal lymphopoietin in differentiated human primary bronchial epithelial cells. <i>Clinical and Experimental Allergy</i> , 2014, 44, 953-964.	2.9	17
71	Allergen immunotherapy with cat allergen peptides. <i>Seminars in Immunopathology</i> , 2004, 25, 391-399.	4.0	16
72	Strategies to Query and Display Allergy-Derived Epitope Data from the Immune Epitope Database. <i>International Archives of Allergy and Immunology</i> , 2013, 160, 334-345.	2.1	16

#	ARTICLE	IF	CITATIONS
73	Peptide Immunotherapy. Immunology and Allergy Clinics of North America, 2006, 26, 321-332.	1.9	14
74	Persistent Treatment Effect Achieved At One Year After Four Doses Of Der p Derived Synthetic Peptide Immuno-Regulatory Epitopes In An Exposure Chamber Model Of House Dust Mite Allergy. Journal of Allergy and Clinical Immunology, 2014, 133, AB289.	2.9	14
75	The Allergic Rhinitis Clinical Investigator Collaborative (AR-CIC): verification of nasal allergen challenge procedures in a study utilizing an investigational immunotherapy for cat allergy. Clinical and Translational Allergy, 2018, 8, 15.	3.2	13
76	Induction of bystander tolerance and immune deviation after Fel d 1 peptide immunotherapy. Journal of Allergy and Clinical Immunology, 2019, 143, 1087-1099.e4.	2.9	13
77	T cell-mediated autoimmunity in immune thrombocytopenia. European Journal of Haematology, 2022, 108, 18-27.	2.2	13
78	Environmental influence on T cell receptor β gene rearrangement and expression in vitro. European Journal of Immunology, 1992, 22, 2733-2736.	2.9	12
79	T Lymphocyte Responses to Nonpolymorphic HLA-Derived Peptides Are Associated With Chronic Renal Allograft Dysfunction. Transplantation, 2011, 91, 279-286.	1.0	12
80	Mechanisms of T Cell Peptide Epitope-Dependent Late Asthmatic Reactions. International Archives of Allergy and Immunology, 2001, 124, 272-275.	2.1	11
81	Increased cytotoxic potential of CD8 ⁺ T cells in immune thrombocytopenia. British Journal of Haematology, 2020, 188, e72-e76.	2.5	11
82	Environmental and allele-specific influences on T cell receptor gene rearrangement: skewed β , γ and δ gene rearrangement patterns in chimeric mice. European Journal of Immunology, 1991, 21, 2943-2949.	2.9	10
83	The potential of peptide immunotherapy in allergy and asthma. Current Allergy and Asthma Reports, 2002, 2, 151-158.	5.3	10
84	Peptide immunotherapy for allergic disease. Expert Opinion on Biological Therapy, 2003, 3, 617-626.	3.1	10
85	Cytokine responses of peripheral blood mononuclear cells to allergen do not identify asthma or asthma phenotypes. Clinical and Experimental Allergy, 2013, 43, 1226-1235.	2.9	10
86	Persistent Treatment Effect with Grass Synthetic Peptide Immuno-Regulatory Epitopes in Grass Allergy Symptoms in an Environmental Exposure Unit Challenge after a Second Season of Natural Pollen Exposure. Journal of Allergy and Clinical Immunology, 2015, 135, AB158.	2.9	10
87	Treatment with anti-cytokine monoclonal antibodies can potentiate the target cytokine rather than neutralize its activity. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 283-285.	5.7	10
88	Concepts and perspectives on peptide-based immunotherapy in allergy. Allergo Journal International, 2016, 25, 144-153.	2.0	10
89	Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections. Viruses, 2021, 13, 2239.	3.3	10
90	The effects of blockade of interleukin 2 receptors and interleukin 4 receptors on cytokine production. Apmis, 1991, 99, 434-442.	2.0	9

#	ARTICLE	IF	CITATIONS
91	Peptide and Recombinant Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2011, 31, 377-389.	1.9	9
92	Methods for Identifying Human Eosinophils in Blood and Tissue. <i>Allergy and Clinical Immunology International</i> , 2002, 14, 0064-0071.	0.3	9
93	Investigating T cell activation and tolerance in vivo: peptide challenge in allergic asthmatics. <i>Cytokine</i> , 2004, 28, 49-54.	3.2	8
94	Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1402-1412.	3.8	8
95	Tumour-associated upregulation of the IL-4 receptor complex. <i>The British Journal of Cancer Supplement</i> , 1990, 10, 96-8.	0.1	8
96	Anti-T cell strategies in the treatment of allergic disease. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2002, 57, 20-23.	5.7	7
97	Fetal thymocyte potential for T cell receptor V β 3-J β 1 junctional modification. <i>European Journal of Immunology</i> , 1993, 23, 1328-1332.	2.9	6
98	Restricted usage of T-cell receptor V β sequence and variable-joining pairs after normal T-cell development and bone marrow transplantation. <i>Human Immunology</i> , 1993, 37, 178-184.	2.4	6
99	Of cats and men: immunodominance and the role of HLA-DP/DQ. <i>Clinical and Experimental Allergy</i> , 2008, 38, 1709-1711.	2.9	6
100	Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat-PAD, the first in a new class of synthetic peptide immunoregulatory epitopes. <i>Clinical and Translational Allergy</i> , 2013, 3, O7.	3.2	6
101	1. Two Year Persistent Treatment Effect Achieved After 4 Doses of Cat-Peptide Antigen Desensitization (Cat-PAD) in an Environmental Exposure Chamber (EEC) Model of Cat Allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB147.	2.9	6
102	Treatment With Synthetic Peptide Immuno-Regulatory Epitopes Derived From Grass Allergens Leads To a Substantial Reduction In Grass Allergy Symptoms In The Environmental Exposure Unit. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB290.	2.9	6
103	Ara h 1 Peptide Immunotherapy Ameliorates Peanut-Induced Anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB158.	2.9	6
104	Peptide Immunotherapy; Short but Long Lasting?. <i>Current Treatment Options in Allergy</i> , 2015, 2, 64-71.	2.2	6
105	Immunological Events Underlying the Induction of T Cell Non-Responsiveness. <i>International Archives of Allergy and Immunology</i> , 1994, 104, 211-215.	2.1	5
106	Enhanced In Vivo Immunogenicity Induced by an Antibody to the IL-4 Receptor-Associated gp200-MR6 Molecule. <i>Scandinavian Journal of Immunology</i> , 1996, 44, 135-142.	2.7	5
107	Changes in interferon- γ production following specific allergen immunotherapy: biology vs methodology. <i>Clinical and Experimental Allergy</i> , 2000, 30, 297-300.	2.9	5
108	Initial Evidence of Sustained Efficacy of House Dust Mite Synthetic Peptide Immuno Regulatory Epitopes 2 Years after a Short Course of Treatment in House Dust Mite (HDM) Allergic Subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB142.	2.9	5

#	ARTICLE	IF	CITATIONS
109	Investigating Immune Gene Signatures in Peripheral Blood from Subjects with Allergic Rhinitis Undergoing Nasal Allergen Challenge. <i>Journal of Immunology</i> , 2017, 199, 3395-3405.	0.8	5
110	Ara h 1 Peptide Immunotherapy Protects Against Peanut-Induced Anaphylaxis in a Dose-Dependent Manner. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB410.	2.9	4
111	Immunological changes in peripheral blood following nasal allergen challenge in subjects with allergic rhinitis pre- and post-peptide immunotherapy: An open-label clinical study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1907-1911.	5.7	4
112	Immunotherapy with Allergen Peptides. <i>Allergy, Asthma and Clinical Immunology</i> , 2007, 03, 53.	2.0	4
113	TNF Receptor Involvement in TNF-Mediated Activities against Syngeneic Malignant and Normal Mouse Thymocytes. <i>Cellular Immunology</i> , 1993, 152, 510-521.	3.0	3
114	Allergen isoforms for immunotherapy: diversity, degeneracy and promiscuity. <i>Clinical and Experimental Allergy</i> , 1999, 29, 1588-1590.	2.9	3
115	Inhalation of allergen-derived T cell peptide epitopes induces isolated late asthmatic reactions with associated local eosinophilia. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, S167-S167.	2.9	3
116	T cell peptide epitope immunotherapy is accompanied by local increases in CD25+T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, S362-S362.	2.9	3
117	Continuing Medical Education: an international reality. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2005, 60, 739-742.	5.7	3
118	Chronic Graft Versus Host Disease Is Associated With an Immune Response to Autologous Human Leukocyte Antigen-Derived Peptides. <i>Transplantation</i> , 2010, 90, 555-563.	1.0	3
119	Concepts and perspectives on peptide-based immunotherapy in allergy. <i>Allergo Journal</i> , 2016, 25, 22-31.	0.1	3
120	Prediction of clinical peanut allergy status among children in Hamilton, Ontario using chart review data collected during 2012-2015. <i>Allergy, Asthma and Clinical Immunology</i> , 2017, 13, 10.	2.0	3
121	Determining MHC Restriction of T-cell Responses. <i>Methods in Molecular Medicine</i> , 2008, 138, 57-72.	0.8	3
122	T and B cell ontogeny and phylogeny. <i>Current Opinion in Immunology</i> , 1988, 1, 203-209.	5.5	2
123	Desensitization (Tolerance) induced by allergen-derived T cell peptide epitopes: Evidence for the induction of linked suppression. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, S261-S261.	2.9	2
124	Late asthmatic reactions provoked by intradermal, but not inhaled, allergen-derived T-cell peptides induce Tolerance to subsequent antigen challenge. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, S281.	2.9	2
125	Peptide Therapy and Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 1331-1332.	5.6	2
126	Induction of Thymic Stromal Lymphopoietin (TSLP) in Airway Epithelium by Recombinant Allergens. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, AB125-AB125.	2.9	2

#	ARTICLE	IF	CITATIONS
127	Safety and Tolerability of Fel d 1-Derived Peptide Antigen Desensitization in Subjects with Controlled Asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB206.	2.9	2
128	The Nasal Allergen Challenge Protocol of the Allergic Rhinitis Clinical Investigator Collaborative (AR-CIC): Validation in a Clinical Trial of Cat Synthetic Peptide Immunoregulatory Epitopes (Cat-SPIRE). <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB142.	2.9	2
129	Peptide-based immunotherapy: new developments. <i>Arbeiten Aus Dem Paul-Ehrlich-Institut (Bundesamt) Tj ETQq1 1,0,784314,rgBT / O</i>	0.0	2
130	111 Attenuation of late cutaneous and asthmatic reactions following administration of short allergen-derived T cell peptide epitopes. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, S380.	2.9	1
131	Allergen-derived T cell peptides in immunotherapy. <i>Revue Francaise D'allergologie Et D'immunologie Clinique</i> , 2003, 43, 59-63.	0.1	1
132	The effects of T cell peptides in patients sensitive to cats. <i>Clinical and Experimental Allergy Reviews</i> , 2004, 4, 252-257.	0.3	1
133	Validation of a Functional Assay of IgE-Facilitated CD23-Dependent Allergen Binding to B Cells to Monitor Clinical Efficacy of Immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, S330.	2.9	1
134	A Bell-Shaped Dose-Dependent Induction of Allergen-Specific Tetramer+ CD4 T Cells and Activated Lung ILC2s Following Epicutaneous Allergen Sensitization in HLA-DR4 Transgenic Mice. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB83.	2.9	1
135	Epicutaneous Allergen Exposure Dose Determines Manifestation of Allergic Airway Disease in Mice. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB395.	2.9	1
136	T-cell responses to house dust mites: bad news for immunotherapy?. <i>Clinical and Experimental Allergy</i> , 1997, 27, 853-855.	2.9	0
137	468 Induction of cutaneous and bronchial hyporesponsiveness by short allergen-derived peptides. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, S154.	2.9	0
138	752 Blood eosinophils from atopic donors express messenger RNA for the α , β , γ , and δ subunits of the high affinity IgE receptor (Fc ϵ RI) and intracellular, but not cell surface, δ subunit protein. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, S253.	2.9	0
139	753 Some pitfalls in measuring human eosinophil numbers in blood and tissues. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, S253.	2.9	0
140	825 Mechanisms of the late asthmatic reaction induced by IgE-independent MHC-restricted T cell peptide epitopes. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, S281.	2.9	0
141	Peptide Immunotherapy in Fel d 1-Sensitized HLA-DR1 Transgenic Mice is Associated with Increased IL-10 but Independent of TGF β and Foxp3 Expression. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, S327.	2.9	0
142	Airway Expression of Calcitonin Gene-Related Peptide in T-Cell Peptide-Induced Late Asthmatic Reactions. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, S188.	2.9	0
143	Development and Preliminary Clinical Evaluation of a Peptide Immunotherapy Vaccine for Cat Allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, AB219-AB219.	2.9	0
144	Suppression of Allergic Airway Inflammation by Low Dose, Intranasally Administered Der p 1 Derived Peptides, in a Murine Model of House Dust Mite Allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, AB241.	2.9	0

#	ARTICLE	IF	CITATIONS
145	Persistent Treatment Effect Achieved at One Year After 4 Doses of Fel d 1-Derived Peptide Immunotherapy in an Environmental Exposure Chamber (EEC) Model of Cat Allergy. Journal of Allergy and Clinical Immunology, 2012, 129, AB144.	2.9	0
146	Strategies to Query and Display Allergy-Derived Epitope Data From the Immune Epitope Database (IEDB). Journal of Allergy and Clinical Immunology, 2013, 131, AB209.	2.9	0
147	Ex-Vivo Allergen Stimulation In Whole Blood: A Novel Approach For Evaluating Mechanisms Of Action Of Synthetic Peptide Immuno-Regulatory Epitopes. Journal of Allergy and Clinical Immunology, 2014, 133, AB223.	2.9	0
148	Airway Tissue, But Not Luminal, Eosinophilia Is Related To The Magnitude Of Airway Hyperresponsiveness In a Transgenic Murine Model Of Cat Allergy. Journal of Allergy and Clinical Immunology, 2014, 133, AB60.	2.9	0
149	The Contribution of Peptide-MHC Affinity to the Efficacy of Peptide Immunotherapy in a Murine Model of Allergic Airways Disease. Journal of Allergy and Clinical Immunology, 2015, 135, AB243.	2.9	0
150	Fel d 1 Peptide Immunotherapy Ameliorates Both Cat and Ovalbumin Responses, in a Dual Allergen Murine Model of Allergic Airways Disease. Journal of Allergy and Clinical Immunology, 2016, 137, AB64.	2.9	0
151	Legends of allergy: Professor A. B. Kay. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1588-1590.	5.7	0
152	Peptide-Based Therapeutic Vaccines for Allergic Diseases: Where Do We Stand?. , 2010, , 79-90.		0
153	Persistent Impairments in Humoral and Cellular Immunity in Patients with Immune Thrombocytopenia Treated with Rituximab: A Sub-Study of a Randomized Controlled Trial. Blood, 2012, 120, 492-492.	1.4	0
154	MHC-restricted, IgE-independent, allergen peptide-induced late asthmatic reactions. Chemical Immunology and Allergy, 2000, 78, 30-8.	1.7	0
155	Anti-IgE therapy combined with SIT: contra. Arbeiten Aus Dem Paul-Ehrlich-Institut (Bundesamt FÄ¼r Tj ETQq1 1 0,784314 rgBT /Over	0,8	0